Tuesday, April 9, 2013

Takeda sues Amneal for patent infringment on Colcrys (colchicine)

In response to Amneal's Para-IV notification challenging patents on Colcrys (colchicine),  Takeda has filed a litigation claiming infringement of its intellectual property rights. Colcrys is approved in the US for the treatment of acute flare in gout patients. Other companies which have also filed a Para-IV on colcrys include Westward pharmaceuticals and Parr. Westward is supposed to have first to file status. Colcrys sells approximately $450m in annual sales

Enter your email address:


Delivered by FeedBurner